Department of Cardiology Erasmus Medical Center Rotterdam the Netherlands.
J Am Heart Assoc. 2020 Dec;9(23):e018427. doi: 10.1161/JAHA.120.018427. Epub 2020 Nov 26.
Patients diagnosed with the same subtype of atrial fibrillation according to our current classification system may differ in symptom severity, severity of the arrhythmogenic substrate, and response to antiarrhythmic therapy. Hence, there is a need for an electrical biomarker as an indicator of the arrhythmogenic substrate underlying atrial fibrillation enabling patient-tailored therapy. The aim of this review is to investigate whether atrial refractoriness, a well-known electrophysiological parameter that is affected by electrical remodeling, can be used as an electrical biomarker of the arrhythmogenic substrate underlying atrial fibrillation. We discuss methodologies of atrial effective refractory period assessment, identify which changes in refractoriness-related parameters reflect different degrees of electrical remodeling, and explore whether these parameters can be used to predict clinical outcomes.
根据我们目前的分类系统诊断出患有相同类型心房颤动的患者,其症状严重程度、心律失常基质严重程度以及对抗心律失常治疗的反应可能不同。因此,需要有一种电生物标志物作为心房颤动下心律失常基质的指标,从而实现个体化治疗。本综述的目的是研究心房有效不应期,这一已知受电重构影响的电生理参数,是否可作为心房颤动下心律失常基质的电生物标志物。我们讨论了心房有效不应期评估的方法学,确定了哪些与不应期相关参数的变化反映了不同程度的电重构,并探讨了这些参数是否可用于预测临床结局。